Factors of poor prognosis for new coronavirus infection in patients with cardiovacular pathology

Aim. To assess the structure of cardiovascular pathology in patients with new coronavirus infection (NCI), to identify factors of poor prognosis in these individuals. Material and methods. The study was conducted on the basis of the COVID-19 infectious diseases hospital of the City Hospital No. 33 of Nizhny Novgorod. The study included 284 patients after applying inclusion and exclusion criteria. All subjects were divided into groups: the main group (n = 207) — patients with NCI and cardiovascular diseases (CVD), as well as comorbid diseases, the comparison group (n = 24) with NCI and CVD, the control group (n = 53) with NCI without any comorbid diseases. Demographic indicators, BMI, laboratory parameters, comorbidity and therapy were analyzed. Results. During the study, it was revealed that the most severe course of COVID-19 is characteristic of the main group, and only among them there were fatal outcomes (25% of cases). Analyzing the prevalence of CVD, it turned out that arterial hypertension was the most common in the main group and in the comparison group, coronary heart disease and heart failure were registered somewhat less frequently. The development of acute cardiovascular accidents occurred only in the main group. A mathematical model was developed to determine the risk of death in patients with NCI who are in the hospital. This model is statistically significant (p < 0.001). Conclusion. The older age of patients, the development of acute myocardial infarction, first identified atrial fibrillation and a decrease in saturation contributed to an increased risk of mortality in patients with NCI and CVD. Among drug therapy, the administration of favipiravir, tocilizumab and statins had a beneficial effect on the outcome of diseases.

1. Clerkin K.J., Fried J.A., Raikhelkar J., Sayer G., Griffin J.M., Masoumi A., Jain S.S., Burkhoff D., Kumaraiah D., Rabbani L., Schwartz A., Uriel N. COVID-19 and cardiovascular disease. Circulation. 2020;141(20):1648–1655. DOI: 10.1161/CIRCULATIONAHA.120.046941

2. Obrezan A.A., Solovieva M.V., Mikhailova L.V., Zaitsev V.V., Kon V.E., Panov A.V. A comorbid cardiological patient who has had a new coronavirus infection. Cardiology: News. Opinions. Education/ 2022;2(29):51–56. (In Russian) DOI: 10.33029/2309-1908--10-2-51-56

3. Shi S., Qin M., Shen B., Cai Y., Liu T., Yang F., Gong W., Liu X., Liang J., Zhao Q., Huang H., Yang B., Huang C. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5(7):802–810. DOI: 10.1001/jamacardio.2020.0950

4. Saltiel A.R., Olefsky J.M. Infl ammatory mechanisms linking obesity and metabolic disease. J. Clin. Invest. 2017;127(1):1–4. DOI: 10.1172/JCI92035

5. Centurión O.A., Scavenius K.E., García L.B., Torales J.M., Miño L.M. Potential Mechanisms of Cardiac Injury and Common Pathways of Infl ammation in Patients With COVID-19. Crit. Pathw. Cardiol. 2021;20(1):44–52. DOI: 10.1097/HPC.0000000000000227

6. Association of Nephrologists. Clinical recommendations “Chronic kidney disease”. 2021. (In Russian) URL: https://cr.minzdrav.gov.ru/schema/469_2

7. Levey A.S., Titan S.M., Powe N.R., Coresh J., Inker L.A. Kidney disease, race, and GFR estimation. Clin. J. Am. Soc. Nephrol. 2020;15(8):1203–1212. DOI: 10.2215/CJN.12791019

8. Kamkin E.G. Prevention, diagnosis and treatment of new coronavirus infection (COVID-19). Version 14. Temporary methodological recommendations: Ministry of Health of the Russian Federation. 2021. (In Russian)

9. Pati S., Mahapatra P., Kanungo S., Uddin A., Sahoo K.C. Managing multimorbidity (multiple chronic diseases) amid COVID-19 pandemic: a community based study from Odisha, India. Frontiers in public health. 2021;8:584408.

10. Mair F.S., Foster H.M., Nicholl B.I. Multimorbidity and the COVID-19 pandemic — An urgent call to action. Book Multimorbidity and the COVID-19 pandemic — An urgent call to action. EditorSAGE Publications Sage UK. London, England, 2020:2235042X20961676.

11. Mills K.T. et al. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation. 2016;134(6):441–450.

12. Balanova Yu.A. Shalnova S.A., Imaeva A.E., Kapustina A.V., Muromtseva G.A., Evstifeeva S.E. et al. Prevalence of arterial hypertension, coverage of treatment and its eff ectiveness in the Russian Federation (data from the observational study ESSAY-RF-2). Rational pharmacotherapy in cardiology. 2019;15(4):450–466. (In Russian) DOI:10.20996/1819-6446-2019-15-4-450-466

13. Yanez N.D. et al. COVID-19 mortality risk for older men and women. BMC public health. 2020;20(1):1–7.

14. McNicol A., Israels S.J. Beyond hemostasis: the role of platelets in infl ammation, malignancy and infection. Cardiovascular and Haematological Disorders-Drug Targets (Formerly Current Drug Targets-Cardiovascular and Hematological Disorders). 2008;8(2):99–117.

15. Sheth A.R. et al. Possible mechanisms responsible for acute coronary events in COVID-19. Medical Hypotheses. 2020;143:110125.

16. Yang H., Liang X., Xu J., Hou H., Wang Y. Meta-analysis of atrial fi brillation in patients with COVID-19. Am. J. Cardiol. 2021;144:152–156.

17. Mountantonakis S.E., Saleh M., Fishbein J., Gandomi A., Lesser M., Chelico J. et al. Atrial fi brillation is an independent predictor for in-hospital mortality in patients admitted with SARS-CoV-2 infection. Heart Rhythm. 2021;18(4):501–507. DOI: 10.1016/j.hrthm.2021.01.018

18. Kow C.S., Hasan S.S. Meta-analysis of eff ect of statins in patients with COVID-19. American Journal of Cardiology. 2020;134:153–155.